financetom
Business
financetom
/
Business
/
Online lender OppFi's Q3 profit beats on higher auto approval rates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Online lender OppFi's Q3 profit beats on higher auto approval rates
Oct 29, 2025 4:39 AM

Overview

* OppFi ( OPFI ) Q3 revenue grows 13.5% yr/yr, setting a company record

* Adjusted EPS for Q3 beats analyst expectations

* Company raises full-year guidance for revenue and adjusted EPS

Outlook

* OppFi ( OPFI ) raises full-year revenue guidance to between $590 mln and $605 mln

* Company expects full-year adjusted net income between $137 mln and $142 mln

* OppFi ( OPFI ) forecasts full-year adjusted EPS between $1.54 and $1.60

Result Drivers

* AUTO-APPROVAL RATE - Increased to 79.1%, improving operating efficiency and contributing to record net income

* STRATEGIC POSITIONING - CEO Todd Schwartz cites Model 6.1 refit, risk-based pricing, and dynamic seasonal modeling as key strategies to mitigate economic volatility

* GUIDANCE RAISE - Co raises EPS guidance for the third time this year, reflecting confidence in ongoing performance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $0.46 $0.32 (4

Adjusted Analysts

EPS )

Q3 EPS $0.77

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for OppFi Inc ( OPFI ) is $14.00, about 28.6% above its October 28 closing price of $9.99

* The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102
Apr 2, 2024
09:45 AM EDT, 04/02/2024 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Tuesday that the European Medicines Agency has accepted its marketing authorization application for RP-L102, an investigational gene therapy for Fanconi Anemia, a rare genetic disorder. The company said its application was based on positive data from a phase 1/2 clinical trial where RP-L102 demonstrated sustained genetic correction,...
WeWork targets Chapter 11 exit by May 31, secures $8 billion in rent reduction
WeWork targets Chapter 11 exit by May 31, secures $8 billion in rent reduction
Apr 2, 2024
(Reuters) -WeWork ( WEWOQ ) said on Tuesday it aimed to emerge from Chapter 11 bankruptcy in the U.S. and Canada by May 31 and had negotiated more than $8 billion, or over 40%, reduction in rent commitments from landlords. The shared office space provider, once privately valued at $47 billion, filed for bankruptcy in November as it racked up...
Appili Therapeutics To be Acquired by Aditxt, Inc.
Appili Therapeutics To be Acquired by Aditxt, Inc.
Apr 2, 2024
09:31 AM EDT, 04/02/2024 (MT Newswires) -- Appili Therapeutics Inc. ( APLIF ) on Tuesday said that it has entered into a definitive arrangement agreement to be acquired by Adivir, a subsidiary of Nasdaq-listed Aditxt Inc. Under the terms of the arrangement agreement, shareholders of Appili will receive 0.002745004 of an Aditxt share and US$0.0467 cash, for implied total consideration...
US FDA approves Abbott's heart valve repair device
US FDA approves Abbott's heart valve repair device
Apr 2, 2024
(Reuters) - Abbott Laboratories ( ABT ) said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries. The device TriClip is approved in more than 50 countries, including Canada and nations in Europe, for treating tricuspid regurgitation (TR), which typically impacts older individuals with multiple...
Copyright 2023-2026 - www.financetom.com All Rights Reserved